AnaptysBio, Inc. Common Stock (ANAB) Stock Price

ANABStock
$58.37+333.53%52W
Market Cap$1.73B
P/E
PEG Ratio
Div yield
Beta0.87

ANAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)48.64%
Price vs S&P 500 (4W)9.10%
VGM Score53.27

ANAB Earnings Surprise History

Q2 25-1.34est. -1.58
Q3 250.52est. -1.25
Q4 251.58est. 0.93

ANAB Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.22
4.29
4.29
4.29

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ANABAnaptysBio, Inc. Common Stock
DBB$58.37
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About AnaptysBio, Inc. Common Stock

AnaptysBio Inc develops immune cell-modulating antibody therapies for inflammatory and autoimmune diseases. The company's lead program, rosnilimab, a PD-1 agonist, is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis. It is also developing ANB032, a BTLA agonist in Phase 2b testing for atopic dermatitis.